Pexidartinib: all 29 studies that test it
Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...RecruitingNCT02390752Phase 1
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerRecruitingNCT01042379Phase 2
- A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in JapanCompletedNCT04703322Phase 2Results posted
- Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With PexidartinibCompletedNCT04526704Phase 4Results posted
- A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCTActive, not recruitingNCT04488822Phase 3Results posted
- Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy ParticipantsCompletedNCT04223635Early Phase 1Results posted
- Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy VolunteersCompletedNCT03901313Phase 1Results posted
- Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)CompletedNCT03291288Phase 1Results posted
- A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated MelanomaCompletedNCT02975700Not applicableResults posted
- Study of Pexidartinib in Asian Subjects With Advanced Solid TumorsCompletedNCT02734433Phase 1Results posted
- PLX3397 Plus Sirolimus in Unresectable Sarcoma and Malignant Peripheral Nerve Sheath TumorsTerminatedNCT02584647Phase 1/2Results posted
- A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid TumorsTerminatedNCT02452424Phase 1/2Results posted
- CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid TumorsCompletedNCT02401815Phase 1/2Results posted
- Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)CompletedNCT02371369Phase 3Results posted
- A Phase 1b Open Label, Dose Escalation Study of PLX3397 in Combination With Vemurafenib in V600-mutated BRAF MelanomaTerminatedNCT01826448Phase 1Results posted
- A Phase 1b/2 Study of PLX3397 + Radiation Therapy + Temozolomide in Patients With Newly Diagnosed GlioblastomaCompletedNCT01790503Phase 1/2Results posted
- Phase Ib/II Study of PLX 3397 and Eribulin in Patients With Metastatic Breast CancerCompletedNCT01596751Phase 1/2Results posted
- Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid TumorsCompletedNCT01525602Phase 1Results posted
- Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)TerminatedNCT01499043Phase 2Results posted
- Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)CompletedNCT01349049Phase 1/2Results posted
- A Phase 2 Study of PLX3397 in Patients With Recurrent GlioblastomaTerminatedNCT01349036Phase 2Results posted
- Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin LymphomaCompletedNCT01217229Phase 2Results posted
- Safety Study of PLX108-01 in Patients With Solid TumorsCompletedNCT01004861Phase 1Results posted
- A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST)CompletedNCT03158103Phase 1
- Effect of Probenecid on Pexidartinib PharmacokineticsCompletedNCT03138759Phase 1
- Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic/Advanced Pancreatic or Colorectal CancersCompletedNCT02777710Phase 1
- PLX3397, Radiation Therapy, and Antihormone Therapy in Treating Patients With Intermediate- or High-Risk Prostate CancerCompletedNCT02472275Phase 1
- PLX3397 KIT in Acral aNd mucOsal MelanomaCompletedNCT02071940Phase 2
- Safety, Pharmacokinetic (PK), Pharmcodynamic (PD), and Drug-Drug Interaction of PLX3397 in Patients With Rheumatoid Arthritis Who Are Receiving MethotrexateWithdrawnNCT01090570Phase 1